Outlook Wealth Advisors LLC Purchases Shares of 428 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Outlook Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 428 shares of the biopharmaceutical company's stock, valued at approximately $305,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. State Street Corp grew its stake in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after buying an additional 61,277 shares during the last quarter. International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock worth $707,759,000 after purchasing an additional 11,499 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company's stock worth $357,945,000 after purchasing an additional 2,270 shares during the last quarter. Finally, Swiss National Bank boosted its stake in Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company's stock valued at $338,079,000 after purchasing an additional 2,000 shares during the period. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on REGN shares. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. Finally, Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:REGN traded down $11.65 during midday trading on Friday, hitting $681.58. 1,106,987 shares of the stock were exchanged, compared to its average volume of 820,084. The business's 50-day moving average price is $741.54 and its 200 day moving average price is $952.59. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market capitalization of $74.90 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.